4-(4-OXO-3-PHENYL-3,4-DIHYDROQUINAZOLIN-2-YLTHIO)PYRIDAZIN-3,6-DIONE


Molecule Category	Free-form
Source	Gaulton A, Kale N, van Westen GJ, Bellis LJ, Bento AP, Davies M, Hersey A, Papadatos G, Forster M, Wege P, Overington JP. A large-scale crop protection bioassay data set. Sci Data. 2015 Jul 7;2:150032. Read more ...


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	YURWJPLSHAUZAY-UHFFFAOYSA-N
Smiles	O=C1C=C(SC2=Nc3ccccc3C(=O)N2c4ccccc4)C(=O)N=N1
InChI	InChI=1S/C18H10N4O3S/c23-15-10-14(16(24)21-20-15)26-18-19-13-9-5-4-8-12(13)17(25)22(18)11-6-2-1-3-7-11/h1-10H

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C18H10N4O3S
Molecular Weight	362.36
AlogP	4.33
Hydrogen Bond Acceptor	7.0
Hydrogen Bond Donor	0.0
Number of Rotational Bond	3.0
Polar Surface Area	116.82
Molecular species	NEUTRAL
Aromatic Rings	2.0
Heavy Atoms	26.0

Assay Description	Organism	Bioactivity
Lipophilicity, log P of the compound	None	2.13
Anticonvulsant activity in ip dosed Mus musculus (mouse) assessed as protection against pentylenetetrazole-induced seizures administered 1 hr before pentylenetetrazole challenge measured after 30 min	Mus musculus	66.0 mg kg-1
Anticonvulsant activity in Mus musculus (mouse) assessed as protection against pentylenetetrazole-induced seizures at 150 mg/kg, ip administered 1 hr before pentylenetetrazole challenge measured after 30 min	Mus musculus	100.0 %
Anticonvulsant activity in Mus musculus (mouse) assessed as protection against pentylenetetrazole-induced seizures at 100 mg/kg, ip administered 1 hr before pentylenetetrazole challenge measured after 30 min	Mus musculus	62.5 %
Anticonvulsant activity in Mus musculus (mouse) assessed as protection against pentylenetetrazole-induced seizures at 50 mg/kg, ip administered 1 hr before pentylenetetrazole challenge measured after 30 min	Mus musculus	37.5 %

Cross References

Resources	Reference
ChEMBL	CHEMBL2234497
PubChem	76333284

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).